The viral death effector Apoptin reveals tumor-specific processes

Apoptosis

Volumn 9, Issue 3, 2004, Pages 315-322

  Rohn, J L ^a   Noteborn, M H M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Apoptin; DEDAF; Drug targets; Epitope shielding; Hippi; Nmi; Nuclear localization; SV40 LT antigen; Tumor specific apoptosis; Tumor specific kinase activity

Indexed keywords

APOPTIN; CASPASE; DNA; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN P53; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; CANCER CELL CULTURE; CELL KILLING; CELL NUCLEUS MEMBRANE; CLINICAL RESEARCH; ENZYME ACTIVITY; HUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; REVIEW; TUMOR CELL DESTRUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BIOPHYSICS; CAPSID; CAPSID PROTEINS; CASPASES; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CHICKEN ANEMIA VIRUS; DNA-BINDING PROTEINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEOME;

EID: 3242757488     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000025808.48885.9c     Document Type: Review

References (49)

1. MacFarlane M. TRAIL-induced signaling and apoptosis. Toxicol Lett 2003; 139: 89-97.
2. Branton PE, Roopchand DE. The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 2001; 20: 7855-7865.
3. Noteborn MHM. Apoptin as an anticancer therapy. In: La Thangue NB and Bandara LR eds. Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins. Humana Press Inc., Totowa, New Jersey, USA, 2002, pp. 275-287.
4. Noteborn MHM. Apoptin-induced apoptosis: A review. Apoptosis 1999; 4: 317-319.
5. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003; 63: 4713-4723.
6. Van der Eb MM, Pietersen AM, Speetjens F, et al. Gene therapy with Apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 2002; 9: 53-61.
7. Shen Z, Wang Y, Zong Y, Qu S. Experimental study on the antitumor effect of chicken anemia virus vp3 gene against liver carcinoma in vivo. Huazhong Uni Sci Technolog Med Sci 2003; 23: 105-115.
8. Ashkenazi A. Targeting death and decoy receptors of the tumour necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
9. LeBlanc HN, Asjkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Diff 2003; 10: 66-75.
10. Greil R, Anether G, Johrere K, Tinhofer I. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: Pathways, targets, and therapeutic tools. J Leukocyte Biol 2003; 74: 311-339.
11. Robert A, Miron M-J, Champagne C, Gingras M-C, Branton PE, Lavoie JN. Distinct cell death pathways triggered by the adenovirus early region 4 ORF 4 protein. J Cell Biol 2002; 158: 519-528.
12. Marcellus RC, Chan H, Paquette D, Thirlwell S, Boivin D, Branton PE. Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the Bα subunit of protein phosphatase 2A. J Virol 2000; 74: 7869-7877.
13. Van Hoof C, Goris J. Phosphatases in apoptosis: To be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta 2003; 1640: 97-104.
14. Noteborn MHM, Danen-van Oorschot AAAM, Van der Eb AJ. Chicken anemia virus: Induction of apoptosis by a single protein of a single-stranded DNA virus. Sem Virol 1998; 8: 497-504.
15. Danen-van Oorschot AAAM. Apoptin, a viral protein that induces tumor-specific apoptosis. Thesis, Leiden University, Leiden, The Netherlands, 2001.
16. Ferreira CG, Epping M, Kruyt FAE, Giaccone G. Apoptosis: Target of cancer therapy. Clin Cancer Res 2002; 8: 2024-2034.
17. Danen-van Oorschot AAAM, Van der Eb AJ, Noteborn MHM. The chicken anemia virus-derived protein Apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 2000; 74: 7072-7078.
18. Noteborn MHM, Van der Eb AJ. Apoptin induces apoptosis in transformed cells specifically: Potentials for an anti-tumor therapy. Biogenic Amines 1999; 15: 73-91.
19. Danen-van Oorschot AAAM, Den Hollander A, Takayama S, Reed J, Van der Eb AJ, Noteborn MHM. BAG-1 inhibits p53-induced but not Apoptin-induced apoptosis. Apoptosis 1997; 2: 395-402.
20. Danen-van Oorschot AAAM, Zhang, Y-H, Erkeland S, Fischer DF, Van der Eb AJ, Noteborn MHM. The effect of Bcl-2 on Apoptin in normal cells versus transformed human cells. Leukemia 1999; 13: S75-S77.
21. Schoop RAL, Kooistra K, Baatenburg de Jong RJ, Noteborn MHM. Bcl-X1 inhibits p53 but not Apoptin-induced apoptosis. Int J Cancer 2004; 109: 38-42.
22. Leliveld SR, Noteborn MHM, Abrahams JP. Prevalent conformations and subunit exchange in the biologically active Apoptin protein multimer. Eur J Biochem 2003; 270: 3619-3627.
23. Leliveld SR, Zhang Y-H, Rohn JL, Noteborn MHM, Abrahams, JP. Apoptin induces tumor-specific apoptosis as a globular multimer. J Biol Chem 2003; 278: 9042-9051.
24. Zhang Y-H, Leliveld SR, Kooistra K, et al. Recombinant Apoptin multimers kill tumor cells but are non-toxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res 2003; 289: 36-46.
25. Danen-Van Oorschot AAAM, Fischer D, Grimbergen JM, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997; 94: 5843-5847.
26. Leliveld SR, Dame RT, Mommaas MA, et al. Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acid Res 2003; 31: 4805-4813.
27. Danen-van Oorschot AAAM, Zhang Y-H, Leliveld SR, et al. Importance of nuclear localization of Apoptin for tumor-specific induction of apoptosis. J Biol Chem 2003; 278: 27729-27736.
28. Guelen L, Paterson H, Gaeken J, Meyers M, Farzaneh F, Tavassoli M. TAT-Apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004; 23: 1153-1165.
29. Snyder EL, Dowdy SF. Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 2001; 3: 147-152.
30. Alvarez M, Rhodes S, Bidwell JP. Context-dependent transcription: all politics are local. Gene 2003; 313: 43-57.
31. Bao J, Zervos AS. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996; 16: 2171-2176.
32. Sun GJ, Tong X, Dong Y, Mei ZZ, Sun ZX. Identification of a protein interacting with Apoptin from human leucocyte cDNA library by using yeast two-hybrid screening. Sheng Wu Hua Xue Sheng Wu Wu Li Xue Bao (Shanghai) 2002; 34: 369-372.
33. Pelengans S, Khan M, Evan G. c-Myc: More than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
34. Danen-van Oorschot AAAM, Voskamp P, Seelen MCMJ, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Diff 2004: epub ahead of print.
35. Cheng C-H, Chen D-Y, Lin Y-M, You C-Y. Cloning and characterization of the Apoptin-associating proteins. Proc 14th Joint Ann Conf Biomed Sci Taipei Taiwan, 1999.
36. Zheng L, Schickling O, Peter ME, Leonardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001; 276: 31945-31952.
37. Schickling O, Stegh AH, Byrd J, Peter M. Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and inhibition of RNA polymerase I dependent transcription. Cell Death Diff 2001; 8: 1157-1168.
38. Stegh AH, Schickling O, Ehret A, et al. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J 1998; 17: 5974-5986.
39. Chan EK, Imai H, Hamel JC, Tan EM. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 1991; 174: 1239-1244.
40. Schlesio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 2002; 21: 5775-5786.
41. Cheng C-M, Huang S-p, Chang Y-F, Chung W-Y, You C-Y. The viral death protein Apoptin interacts with Hippi, the protein interactor of Huntingtin-mteracting protein 1. Biochim Biophys Res Com 2003; 305: 359-364.
42. Gervais FG, Singaraja R, Xanthoudakis S, et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 2002; 4: 95-105.
43. Rohn JL, Zhang Y-H, Aalbers RIJM, et al. A tumor-specific kinase activity regulates the viral death protein Apoptin. J Biol Chem 2002; 277: 50820-50827.
44. Peters MA, Jackson DC, Crabb BS, Browning GF. Chicken anemia virus VP2 is a novel dual specificity protein phosphatase. J Biol Chem 2002; 277: 39566-39573.
45. Zhang Y-H, Abrahams PJ, Van der Eb AJ, Noteborn MHM. The viral protein Apoptin induces apoptosis in UV-C-irradiated cells from individuals with various hereditary cancer-prone syndromes. Cancer Res 1999; 59: 3010-3015.
46. Zhang Y-H, Kooistra K, Pietersen AM, Rohn JL, Noteborn MHM. Activation of the tumor-specific death effector Apoptin and its kinase by an N-terminal determinant of SV40 large T antigen. Submitted.
47. Lu Y, Lian H, Sharma P, et al. Disruption of the cockayne syndrome B gene impairs spontaneous tumorigenesis in cancer-predisposed Ink4a/ARF knockout mice. Mol Cell Biol 2001; 21: 1810-1818.
48. Zhang Y-H. Activation of Apoptin, a tumor-specific viral death effector. Thesis, Leiden University, The Netherlands, 2004.
49. Pietersen AM. Preclinical studies with Apoptin. Thesis, Erasmus University, Rotterdam, The Netherlands, 2003.